Our Pipeline

We have translated from our cutting-edge proteomics datasets into two types of "markers", details coming soon...

Biomarker:  we have validated various biomarkers for multiple mental diseases, aiming for innovative molecular diagnostics products in a field with none available. 

Drug target: our drug targets originate from patients' proteomic insights covering various diseases, including oncology, CNS and liver diseases. Multiple lead molecules have been identified and are under further development.

Our Research Strategy is From Bed to Bed